HC Wainwright Issues Optimistic Estimate for AARD Earnings

Aardvark Therapeutics, Inc. (NASDAQ:AARD) – HC Wainwright raised their Q3 2026 earnings estimates for shares of Aardvark Therapeutics in a research report issued to clients and investors on Monday, October 19th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.55) per share for the quarter, up from their previous forecast of ($0.94). HC Wainwright has a “Neutral” rating and a $4.00 price objective on the stock. The consensus estimate for Aardvark Therapeutics’ current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Aardvark Therapeutics’ Q4 2026 earnings at ($0.50) EPS, FY2026 earnings at ($2.69) EPS, Q1 2027 earnings at ($0.44) EPS, Q2 2027 earnings at ($0.44) EPS, Q3 2027 earnings at ($0.41) EPS, Q4 2027 earnings at ($0.45) EPS and FY2027 earnings at ($1.74) EPS.

Aardvark Therapeutics (NASDAQ:AARD) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.21.

A number of other research analysts have also recently commented on the company. Wall Street Zen upgraded Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aardvark Therapeutics in a research report on Tuesday, September 29th. UBS Group set a $4.00 target price on Aardvark Therapeutics in a research note on Monday. Royal Bank Of Canada reissued a “sector perform” rating and set a $6.00 target price on shares of Aardvark Therapeutics in a research note on Thursday, September 24th. Finally, BTIG Research restated a “neutral” rating on shares of Aardvark Therapeutics in a report on Monday, October 12th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Aardvark Therapeutics has a consensus rating of “Hold” and a consensus target price of $11.89.

Aardvark Therapeutics Price Performance

Shares of NASDAQ AARD opened at $3.90 on Wednesday. The company has a 50 day simple moving average of $5.45 and a 200-day simple moving average of $5.29. The company has a market capitalization of $85.33 million, a P/E ratio of -1.21 and a beta of 3.80. Aardvark Therapeutics has a 1 year low of $3.35 and a 1 year high of $16.60.

Insider Activity

In other news, insider Nelson Sun sold 62,000 shares of the stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $5.18, for a total transaction of $321,160.00. Following the sale, the insider owned 35,475 shares of the company’s stock, valued at approximately $183,760.50. This represents a 63.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 17.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in AARD. BlackRock Inc. acquired a new position in shares of Aardvark Therapeutics in the second quarter valued at approximately $1,077,000. Renaissance Technologies LLC acquired a new stake in Aardvark Therapeutics during the 1st quarter worth approximately $267,000. J. Goldman & Co LP purchased a new position in Aardvark Therapeutics in the 2nd quarter valued at approximately $233,000. Ieq Capital LLC acquired a new position in shares of Aardvark Therapeutics in the second quarter worth $221,000. Finally, Susquehanna International Group LLP acquired a new position in shares of Aardvark Therapeutics in the second quarter worth $138,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in San Diego, California. The company develops novel therapies for obesity and other metabolic diseases, with a focus on treatments designed to regulate appetite and food intake.

Its lead investigational product, AARD-001, is an orally administered small-molecule candidate intended to activate bitter taste receptors and stimulate signaling pathways in the gastrointestinal tract that may influence appetite and satiety.